Clinical Trials on COPD(Chronic Obstructive Pulmonary Disease) in United States

Total 18975 results

Novartis Pharmaceuticals

Completed

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

Chronic Obstructive Pulmonary Disease (COPD)

United States
JHSPH Center for Clinical Trials
National Heart, Lung, and Blood Institute (NHLBI)

Not yet recruiting

Multi-Center Clean Air Randomized Controlled Trial in COPD (Clean Air)

Chronic Obstructive Pulmonary Disease (COPD)

United States
VA Puget Sound Health Care System
University of Washington; Public Health - Seattle and King County

Completed

Chronic Obstructive Pulmonary Disease and Community Health Worker Home-visits

COPD

United States
National Jewish Health

Terminated

The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease

COPD

United States
Medicines Evaluation Unit Ltd
Chiesi UK

Completed

A Study Comparing the Effects of Trimbow to Fostair in COPD (TRIFLOW)

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Kaiser Permanente
Merck Sharp & Dohme LLC

Completed

A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease

Asthma | COPD

United States
Xiromed LLC
Laboratorios Liconsa; Exeltis

Completed

Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD) (ARBORUS)

COPD

United States, India
Novartis Pharmaceuticals

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (SHINE)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Russian Federation, Taiwan, Canada, Germany, Philippines, South Africa, Spain, United Kingdom, Turkey, Hungary, Guatemala, Australia, Bulgaria, France, Poland, Switzerland, Slovakia, Japan
Northwestern University
Department of Health and Human Services

Completed

Respiratory Infection Monitoring

Chronic Obstructive Pulmonary Disease (COPD)

United States
Medtronic Cardiac Rhythm and Heart Failure

Completed

Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Chiesi Farmaceutici S.p.A.

Completed

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease (GLIMMER)

Chronic Obstructive Pulmonary Disease | COPD

United States
AstraZeneca

Completed

OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)

Chronic Obstructive Pulmonary Disease | COPD

United States, France, Poland, South Africa, Canada, Germany
Chiesi Farmaceutici S.p.A.

Completed

Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
AstraZeneca

Completed

A First Time in Man Study to Asses the Safety and Tolerability of AZD7624 in Healthy Subjects

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
AstraZeneca

Recruiting

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations. (TITANIA)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, Germany, United Kingdom, China, Philippines, Italy, Chile, Taiwan, Thailand, France, Puerto Rico, Israel, Peru, Colombia, Poland, Brazil, Russian Federation, Romania, Greece
Weill Medical College of Cornell University

Completed

The Natural History of Gene Expression in the Lung Cells of Non-Smokers, Smokers and Ex-Smokers in Health and Disease

Smoking | Smoking Cessation | Emphysema | Chronic Obstructive Pulmonary Disease (COPD) | Chronic Bronchitis

United States
Aerocrine AB

Completed

Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States
Edmond Pharma

Unknown

The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD) (RESTORE)

Chronic Obstructive Pulmonary Disease (COPD)

Belgium, Bulgaria, Czech Republic, Denmark, France, Italy, Poland, Romania, Slovakia, United Kingdom
BioMarck Pharmaceuticals, Ltd.
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD (BREATH-1)

Chronic Obstructive Pulmonary Disease | COPD

United States
Pfizer

Completed

Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (GLOW6)

Chronic Obstructive Pulmonary Disease (COPD)

Greece, Belgium, Bulgaria, Turkey, Hungary, Slovakia, Spain, United Kingdom, Russian Federation, Ireland
Renown Health
Fisher and Paykel Healthcare

Terminated

AIRVO Device Intervention for Moderate to Severe COPD (AIRVO)

COPD | COPD Exacerbation

United States
AstraZeneca

Completed

A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Germany, Argentina, Bulgaria, Poland, Turkey, Mexico, United Kingdom
Novartis Pharmaceuticals

Completed

The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD) (QUANTIFY)

Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca

Completed

Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Austria, Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Italy, Lithuania, Netherlands, Poland, South Africa, Spain, United Kingdom
AstraZeneca

Completed

Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination

Chronic Obstructive Pulmonary Disease (COPD)

Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Sweden, Ukraine, United Kingdom
Wake Forest University Health Sciences

Terminated

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

COPD | COPD Exacerbation

United States
Pearl Therapeutics, Inc.

Completed

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Chelsea and Westminster NHS Foundation Trust

Completed

Aerogen Nebuliser Versus Standard Nebulised Therapy in Acute Chronic Obstructive Pulmonary Disease

COPD

United Kingdom
Novartis Pharmaceuticals

Completed

A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

United States, Romania, Hungary, Bulgaria, Spain, Finland, Puerto Rico
Novartis Pharmaceuticals

Completed

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

United States, Colombia, Egypt, Hungary, France, Guatemala, Panama, Slovakia, Slovenia
Duke University
Boehringer Ingelheim

Terminated

The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort

Emphysema | Chronic Obstructive Pulmonary Disease (COPD) | Chronic Bronchitis

United States
Novartis

Completed

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States, Argentina, Germany, Spain, Canada, India, Turkey, Sweden, Italy
VA Office of Research and Development

Completed

Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease (TADA-PHILD)

Pulmonary Hypertension | Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca

Recruiting

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO). (PROSPERO)

Chronic Obstructive Pulmonary Disease (COPD)

China, Denmark, United States, Australia, Germany, Netherlands, Poland, Spain, United Kingdom, Korea, Republic of, Philippines, Italy, Argentina, Belgium, Bulgaria, Canada, Czechia, Finland, Hungary, India, Japan, Mexico, Norway, Port... and more
University of California, San Francisco
National Institute of Nursing Research (NINR)

Completed

Dyspnea Self-Management: Internet or Face-to-Face

Chronic Obstructive Pulmonary Disease (COPD)

United States
AstraZeneca

Active, not recruiting

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD. (CRESCENDO)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Denmark, Italy, United Kingdom, Canada, Germany, Turkey, Argentina, South Africa, Spain, Poland, Bulgaria, Mexico, Netherlands
AstraZeneca
Amgen

Completed

Tezepelumab COPD Exacerbation Study (COURSE)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Denmark, France, United Kingdom, Korea, Republic of, Germany, Israel, Spain, Netherlands
Novartis Pharmaceuticals

Completed

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Chronic Obstructive Pulmonary Disease (COPD)

United States, Poland, Romania, Canada, Philippines, Spain, Ukraine, Vietnam
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
AstraZeneca

Recruiting

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (MIRANDA)

Chronic Obstructive Pulmonary Disease (COPD)

China, United States, Denmark, Italy, Germany, Hungary, Netherlands, Spain, United Kingdom, Belgium, Argentina, Bulgaria, Canada, India, Japan, Vietnam, Brazil, Malaysia, Thailand, France, Mexico, Greece, Poland, Korea, Republic of, Peru, Chil... and more
Novartis Pharmaceuticals

Completed

Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Belgium, Poland, Romania, Croatia, Estonia, Netherlands, Slovakia, Latvia, Lithuania, United Kingdom, Argentina, Bulgaria, Serbia, Austria, Hungary, Spain, Greece, Canada, Denmark, Czechia
AstraZeneca

Recruiting

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (OBERON)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Czechia, Denmark, Hungary, Netherlands, Spain, Korea, Republic of, Argentina, Belgium, Bulgaria, Finland, India, Japan, Mexico, Norway, Sweden, Turkey, Vietnam, Portugal, Puerto Rico
AstraZeneca

Completed

The Use of a Forecasting System for Predicting Exacerbations of COPD

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
AstraZeneca

Completed

European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Sweden, France, Italy, Spain, Turkey, United Kingdom, Germany, Denmark, Finland, Netherlands, Norway, Austria, Belgium, Portugal, Greece, Ireland, Switzerland
Novartis Pharmaceuticals

Completed

QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Colombia, India, Korea, Republic of, Poland, Romania, South Africa, Italy, Austria, Belgium, Croatia, Estonia, Hungary, Russian Federation, Taiwan, Turkey, Japan, Spain, Sweden, United Kingdom, China, Thailand, Canada, Hong Kong and more
Imperial College London
AstraZeneca

Withdrawn

GR Defect in Sputum Cells in COPD

Chronic Obstructive Pulmonary Disease (COPD)

United Kingdom
AstraZeneca

Recruiting

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD

COPD (Chronic Obstructive Pulmonary Disease)

United States, Korea, Republic of, Argentina, Turkey, Vietnam, Malaysia, Philippines, Thailand, Hungary, Mexico, Canada, India, Bulgaria, Poland
Imperial College London
Duska Scientific Co.

Completed

ATP/AMP Challenge in Healthy Non-smokers, Smokers, Patients With Asthma, and Patients With Chronic Obstructive Pulmonary Disease (COPD)

Smoking | Asthma | COPD

United Kingdom
EpiEndo Pharmaceuticals
FGK Clinical Research GmbH

Completed

Clinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD

Chronic Obstructive Pulmonary Disease | COPD

Germany, United Kingdom

Clinical Trials on COPD(Chronic Obstructive Pulmonary Disease) in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations